Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

RG 1678

Known as: RG-1678, RG1678 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
IMPORTANCE In schizophrenia, the severity of negative symptoms is a key predictor of long-term disability. Deficient signaling… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2014
2014
In this issue, Umbricht and colleagues1 reported improvement of negative symptoms of schizophrenia associated with 2 of 3 doses… Expand
Is this relevant?
2014
2014
Bitopertin (RG1678) is a glycine reuptake inhibitor in phase 3 trials for treatment of schizophrenia. Its clinical oral… Expand
  • table I
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2013
2013
Deficient N-methyl-D-aspartate (NMDA) receptor transmission is thought to underlie schizophrenia. An approach for normalizing… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2013
2013
We characterize a novel radioligand for the glycine transporter type 1 (GlyT1), [(11)C]RO5013853, in humans. Ten healthy male… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Dysfunctional N-methyl-d-aspartate (NMDA) receptor neurotransmission has been implicated in the pathophysiology of schizophrenia… Expand
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • figure 5
Is this relevant?
Review
2012
Review
2012
  • D. C. Javitt
  • Handbook of experimental pharmacology
  • 2012
  • Corpus ID: 10931475
Schizophrenia is a severe neuropsychiatric disorder without adequate current treatment. Recent theories of schizophrenia focus on… Expand
Is this relevant?
2012
2012
BACKGROUND Bitopertin (RG1678) is a selective glycine reuptake inhibitor currently in Phase III development for the treatment of… Expand
Is this relevant?
Review
2011
Review
2011
RG1678 is a glycine transporter-1 inhibitor currently in Phase III trials for the treatment of the negative symptoms of… Expand
  • figure 1
Is this relevant?
Highly Cited
2010
Highly Cited
2010
The GlyT1 transporter has emerged as a key novel target for the treatment of schizophrenia. Herein, we report on the optimization… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?